Acuitas Therapeutics and Researchers at the University of Pennsylvania Demonstrate Enhanced T Cell Immunity with IL-12 mRNA-LNP Adjuvant
VANCOUVER, BC – Acuitas Therapeutics announced the publication of a new study in Science Immunology, titled “An IL12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses.” The study demonstrates… Read More